Adcock Ingram to Delist Amidst Corporate Changes
Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.
This article is for Health Matters subscribers
Subscribers read every article in full, receive the daily briefing and have access to the complete archive.
SubscribeLog in
-
Adcock Ingram, Bidvest, Corporate News, healthcare, Johannesburg Stock Exchange, JSE, Mergers & Acquisitions, Natco Pharma, Panado, pharmaceuticals, South African Business